MarketPulse

obesity drug

4 articles
BenzingaBenzinga··Vandana Singh

Rhythm Pharma's Obesity Drug Fails Primary Trial, Pivots to Next-Gen Candidates

Rhythm Pharmaceuticals' setmelanotide fails EMANATE Phase 3 primary endpoints for rare genetic obesity, sending stock down 4.98%. Company pivots to next-generation MC4R agonists.
RYTMbiotechclinical trial failure
BenzingaBenzinga··Vandana Singh

AbbVie's Obesity Drug Shows Promise With Up to 10% Weight Loss in Early Trial

AbbVie reports Phase 1 data for obesity treatment ABBV-295, showing 7.75%-9.79% weight loss. Stock declined despite positive results amid broader market pressure.
ABBVXLVIYHclinical trialweight loss
BenzingaBenzinga··Vandana Singh

Roche's Obesity Drug Falls Short of GLP-1 Rivals in Phase 2 Results

Roche's obesity drug petrelintide achieved 10.7% weight loss in Phase 2 trials but significantly trails GLP-1 rivals Novo Nordisk and Eli Lilly, triggering sharp stock declines.
LLYNVORHHBYclinical trial resultsweight loss
BenzingaBenzinga··Vandana Singh

Novo Nordisk's China Obesity Treatment Achieves 19.7% Weight Loss in Phase 2 Trial

Novo Nordisk's obesity drug UBT251 achieved 19.7% weight loss in Phase 2 trials for Chinese patients, offsetting recent setbacks from a failed competitor drug trial.
LLYNVOclinical trialweight loss